In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Startups and Alliances: Between a Rock and a Hard Place

Executive Summary

Development’s more expensive, markets are smaller, investors are meaner. But alliances aren’t the answer. Or at least not the answer anyone wants to hear. It's time to rethink the anti-alliance logic, which may require a new approach to starting up device companies.

You may also be interested in...



Swiss Finally Beat EMA On New Drug Approval Times

More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.

Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount

The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.

ICH Finalizes Guide To Cutting Down On Rat Carcinogenicity Studies

An ICH guideline describes the “weight of evidence” criteria that in some cases may provide an adequate assessment of human carcinogenicity risk without the need for data from a two-year rat carcinogenicity study.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV000208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel